| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Insider buying and selling activity across 114 companies in the Pharmaceuticals industry. Part of the Health Care sector.
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | 3M | 12M | SEC |
|---|---|---|---|---|---|---|---|---|---|---|---|
| May 10, 2023 | ESPR Esperion Therapeutics, Inc. | Rocamboli Stephen | Director | Buy | 8,111 | $1.50 | $12,125.95 | New | +11.0% | +43.2% | |
| May 9, 2023 | HIMS Hims & Hers Health, Inc. | Baird Melissa | Chief Operating Officer | Sell | 12,966 | $10.78 | $139,806.82 | -1.5% | -25.8% | +14.1% | |
| May 9, 2023 | ALKS Alkermes Plc. | Wysenski Nancy | Director | Sell | 41,250 | $31.24 | $1,288,786.13 | -72.3% | -9.2% | -22.1% | |
| May 9, 2023 | AVDL Avadel Pharmaceuticals Plc | Palczuk Linda78 | Director | Buy | 2,500 | $14.76 | $36,900.00 | +5.0% | -11.0% | +8.0% | |
| May 9, 2023 | ESPR Esperion Therapeutics, Inc. | Koenig Sheldon L.60 | President And CEO | Buy | 20,000 | $1.26 | $25,192.00 | +6.8% | +12.0% | +43.7% | |
| May 9, 2023 | PLSH Panacea Life Sciences Holdings, Inc. | Buttorff Leslie | CEO | Buy | 15,300 | $0.47 | $7,147.10 | +0.7% | - | - | |
| May 8, 2023 | IRWD Ironwood Pharmaceuticals Inc | McCourt Thomas A66 | Chief Executive Officer | Sell | 21,148 | $10.62 | $224,591.76 | -2.5% | +8.0% | -22.7% | |
| May 8, 2023 | HIMS Hims & Hers Health, Inc. | Baird Melissa | Chief Operating Officer | Sell | 31,998 | $11.95 | $382,482.16 | -1.9% | -33.3% | +4.2% | |
| May 8, 2023 | PFE Pfizer Inc | Gottlieb Scott | Director | Buy | 2,000 | $38.50 | $77,005.00 | +22.2% | -7.7% | -28.2% | |
| May 5, 2023 | UTHR United Therapeutics Corp | Mesa Nilda47 | Director | Sell | 374 | $214.81 | $80,337.07 | -6.1% | +8.3% | +22.5% | |
| May 5, 2023 | ASRT Assertio Holdings, Inc. | Tyree James L51 | Director | Sell | 43,143 | $6.00 | $258,767.40 | -20.5% | -13.0% | -83.3% | |
| May 4, 2023 | MRK Merck & Co., Inc. | Zachary Jennifer | EVP, General Counsel | Sell | 19,141 | $117.59 | $2,250,834.21 | -35.3% | -9.3% | +11.6% | |
| May 4, 2023 | ETST Earth Science Tech, Inc. | Saumat Giorgio R. | CEO | Buy | 2,000,000 | $0.01 | $10,000.00 | +2.0% | - | - | |
| May 4, 2023 | HIMS Hims & Hers Health, Inc. | Becklund Irene | Pao | Sell | 566 | $11.68 | $6,610.88 | -100% | -28.6% | -4.0% | |
| May 4, 2023 | DVAX Dynavax Technologies Corp | Novack David F73 | President &COO | Sell | 17,515 | $10.90 | $190,913.50 | -84.6% | +24.1% | +7.6% | |
| May 4, 2023 | UTHR United Therapeutics Corp | Mahon Paul A47 | EVP &General Counsel | Sell | 6,000 | $215.82 | $1,294,903.37 | -3.8% | +11.6% | +21.6% | |
| May 4, 2023 | MRK Merck & Co., Inc. | Karachun Rita A | Sr. VP Fince-global Controller | Sell | 15,875 | $117.53 | $1,865,842.73 | -25.8% | -9.3% | +11.6% | |
| May 3, 2023 | YCBD Cbdmd, Inc. | Kennedy Thomas Ronan | Interim CEO And CFO | Buy | 5,000 | $2.10 | $10,500.00 | +342.0% | -25.9% | -54.4% | |
| May 3, 2023 | MRK Merck & Co., Inc. | Mizell Steven52 | EVP, Chief Hr Officer | Sell | 53,400 | $119.01 | $6,355,056.10 | -23.9% | -10.4% | +11.5% | |
| May 3, 2023 | BMY Bristol Myers Squibb Co | Vessey Rupert53 | EVP &President, Research | Sell | 50,385 | $67.06 | $3,378,818.10 | -51.3% | -7.7% | -34.4% | |
| May 3, 2023 | LLY Eli Lilly & Co | Lilly Endowment Inc | 10% Owner | Sell | 178,302 | $426.40 | $76,028,737.75 | - | +5.1% | +75.3% | |
| May 2, 2023 | UTHR United Therapeutics Corp | Rothblatt Martine A58 | Chairperson &CEO | Sell | 8,000 | $228.59 | $1,828,684.81 | -51.5% | +6.1% | +11.5% | |
| May 2, 2023 | LLY Eli Lilly & Co | Lilly Endowment Inc | 10% Owner | Sell | 41,698 | $409.75 | $17,085,591.63 | - | +12.5% | +92.2% | |
| May 2, 2023 | MRK Merck & Co., Inc. | Williams David Michael | EVP,Chief Info&Digital Officer | Sell | 7,509 | $116.82 | $877,222.41 | -40.4% | -8.9% | +12.2% | |
| May 1, 2023 | NBIX Neurocrine Biosciences Inc | Rastetter William H48 | Director | Sell | 4,300 | $101.43 | $436,135.24 | -9.1% | -2.0% | +32.2% |
The blue line has two modes, toggled with the Relative and Absolute buttons:
Relative (default) shows cumulative industry performance with both the overall market and parent sector movements removed. When the line rises above 100, the industry is outperforming its sector; below 100 means underperforming. This is calculated using factor returns via weighted least squares (WLS) regression, isolating pure industry-specific behavior.
Absolute shows the total cumulative return of the industry including market and sector movement. This reflects what an investor actually experienced — an industry can show strong absolute gains even while underperforming its sector in relative terms.
Both views start at an index of 100. Other return drivers such as momentum, value, or size are deliberately retained in both modes, since these are part of what makes an industry behave the way it does and may reflect the conditions insiders are responding to.